Krebs Biochemicals Industries Ltd leads gainers in B group - Business Standard
KILITCH Stock | 307.45 2.60 0.84% |
Under 61% of Kilitch Drugs' investor base is looking to short. The analysis of overall sentiment of trading Kilitch Drugs Limited stock suggests that many investors are alarmed at this time. Kilitch Drugs' investing sentiment shows overall attitude of investors towards Kilitch Drugs Limited.
Kilitch |
Krebs Biochemicals Industries Ltd leads gainers in B group Business Standard
Read at news.google.com
Kilitch Drugs Fundamental Analysis
We analyze Kilitch Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kilitch Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kilitch Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Kilitch Drugs is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Kilitch Drugs Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kilitch Drugs stock to make a market-neutral strategy. Peer analysis of Kilitch Drugs could also be used in its relative valuation, which is a method of valuing Kilitch Drugs by comparing valuation metrics with similar companies.
Peers
Kilitch Drugs Related Equities
SUMICHEM | Sumitomo Chemical | 8.18 | ||||
NEOGEN | Neogen Chemicals | 8.01 | ||||
TIRUMALCHM | Thirumalai Chemicals | 1.54 | ||||
DMCC | DMCC SPECIALITY | 1.46 | ||||
TATACHEM | Tata Chemicals | 1.13 | ||||
EMBASSY | EMBASSY OFFICE | 0.03 | ||||
POCL | Pondy Oxides | 1.22 |
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |